EUR 11.61
(-0.29%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 52.81 Million EUR | -2.68% |
2022 | 51.32 Million EUR | 48.14% |
2021 | 34.67 Million EUR | 164.01% |
2020 | 13.12 Million EUR | -19.35% |
2019 | 16.39 Million EUR | 90.17% |
2018 | 8.55 Million EUR | 17.29% |
2017 | 7.28 Million EUR | 1096.42% |
2016 | -712 Thousand EUR | -359.47% |
2015 | 1.1 Million EUR | -384.93% |
2014 | -32.85 Thousand EUR | 80.54% |
2013 | -149.75 Thousand EUR | 11.07% |
2012 | -189.88 Thousand EUR | -179.57% |
2011 | 59.37 Thousand EUR | 244.49% |
2010 | -165.16 Thousand EUR | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q1 | 11.73 Million EUR | 7.41% |
2024 Q2 | 12.83 Million EUR | 13.58% |
2023 Q4 | 10.92 Million EUR | -30.31% |
2023 Q3 | 15.67 Million EUR | 23.85% |
2023 FY | - EUR | -2.68% |
2023 Q1 | 13.3 Million EUR | 30.59% |
2023 Q2 | 12.65 Million EUR | -4.87% |
2022 Q1 | 13.3 Million EUR | 78.12% |
2022 Q2 | 13.52 Million EUR | 1.62% |
2022 FY | - EUR | 48.14% |
2022 Q3 | 14.31 Million EUR | 5.87% |
2022 Q4 | 10.18 Million EUR | -28.82% |
2021 Q3 | 9.61 Million EUR | 5.44% |
2021 Q1 | 8.47 Million EUR | 109.23% |
2021 Q4 | 7.46 Million EUR | -22.3% |
2021 FY | - EUR | 164.01% |
2021 Q2 | 9.11 Million EUR | 7.54% |
2020 Q3 | 2.97 Million EUR | 46.74% |
2020 Q2 | 2.02 Million EUR | -50.25% |
2020 Q1 | 4.07 Million EUR | 23.62% |
2020 Q4 | 4.05 Million EUR | 36.29% |
2020 FY | - EUR | -19.35% |
2019 Q3 | 6.02 Million EUR | 64.39% |
2019 Q1 | 3.42 Million EUR | 33.43% |
2019 FY | - EUR | 90.17% |
2019 Q4 | 3.29 Million EUR | -45.35% |
2019 Q2 | 3.66 Million EUR | 7.22% |
2018 Q3 | 2.56 Million EUR | 57.61% |
2018 FY | - EUR | 17.29% |
2018 Q2 | 1.62 Million EUR | 0.0% |
2018 Q1 | 1.62 Million EUR | 0.27% |
2018 Q4 | 2.56 Million EUR | 0.0% |
2017 FY | - EUR | 1096.42% |
2017 Q1 | 2.02 Million EUR | 243.02% |
2017 Q2 | 2.02 Million EUR | -0.0% |
2017 Q3 | 1.62 Million EUR | -19.8% |
2017 Q4 | 1.62 Million EUR | 0.0% |
2016 Q4 | -1.41 Million EUR | 0.0% |
2016 Q1 | 1.04 Million EUR | 0.0% |
2016 Q2 | 1.04 Million EUR | 0.0% |
2016 Q3 | -1.41 Million EUR | -235.09% |
2016 FY | - EUR | -359.47% |
2015 FY | - EUR | -384.93% |
2014 FY | - EUR | 80.54% |
2013 FY | - EUR | 11.07% |
2012 FY | - EUR | -179.57% |
2011 FY | - EUR | 244.49% |
2010 FY | - EUR | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Cegedim SA | 95.25 Million EUR | 44.551% |
Guerbet SA | 90.09 Million EUR | 41.377% |
Nexus AG | 53.43 Million EUR | 1.151% |
Bastide Le Confort Médical SA | 110.32 Million EUR | 52.126% |
Revenio Group Oyj | 30.09 Million EUR | -75.527% |
Drägerwerk AG & Co. KGaA | 318.33 Million EUR | 83.409% |
Sartorius Aktiengesellschaft | 811.2 Million EUR | 93.489% |
LNA Santé SA | 144.63 Million EUR | 63.483% |
Siemens Healthineers AG | 4.22 Billion EUR | 98.75% |
Equasens Société anonyme | 71.29 Million EUR | 25.923% |
Stratec SE | 39.82 Million EUR | -32.634% |